These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11061029)

  • 21. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?
    Holzheimer RG
    Infection; 1998; 26(2):77-84. PubMed ID: 9561376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.
    Hartenauer U; Weilemann LS; Bodmann KF; Ritzerfeld WW; Asmus S; Koch EM
    J Hosp Infect; 1990 Apr; 15 Suppl A():61-4. PubMed ID: 1971647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Known bacterial virulence factors do not explain the variation in urinary cytokine levels in patients with urosepsis.
    Prins JM; Schultsz C; Speelman P; van Deventer SJ
    FEMS Immunol Med Microbiol; 1996 Dec; 16(3-4):283-9. PubMed ID: 9116647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefpirome versus ceftazidime in the treatment of urinary tract infections.
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():95-104. PubMed ID: 1601765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
    Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
    Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
    Heine HS; Louie A; Adamovicz JJ; Amemiya K; Fast RL; Miller L; Opal SM; Palardy J; Parejo NA; Sörgel F; Kinzig-Schippers M; Drusano GL
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3276-84. PubMed ID: 24687492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential antibiotic-induced release of endotoxin from gram-negative bacteria.
    Bucklin SE; Fujihara Y; Leeson MC; Morrison DC
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 1():S43-51. PubMed ID: 7821304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients.
    Mock CN; Jurkovich GJ; Dries DJ; Maier RV
    Arch Surg; 1995 Nov; 130(11):1234-40; discussion 1240-1. PubMed ID: 7487468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensively drug-resistant Alcaligenes faecalis infection.
    Huang C
    BMC Infect Dis; 2020 Nov; 20(1):833. PubMed ID: 33176714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime.
    Jackson JJ; Kropp H
    J Infect Dis; 1992 Jun; 165(6):1033-41. PubMed ID: 1583320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.